Danielle Bucco

Expert Discusses Exciting Advancements in Treating GI Cancers

January 08, 2018

The role of precision medicine has become a significant area of study, specifically with genomics and liquid biopsies. With the introduction of next-generation sequencing and an improvement in the understanding of molecular alterations, treatments for patients have begun to be individualized.

Changing the Sequence of Therapies Can Improve Results in NSCLC

December 26, 2017

The variety of treatment options now available for non-small cell lung cancer (NSCLC) — including checkpoint inhibitors and targeted therapies — presents challenges in choosing the right treatment plan.

Immunotherapy Is Entering the Stage 3 Lung Cancer Landscape

December 22, 2017

Imfinzi (durvalumab), a PD-L1 inhibitor, is being reviewed for a supplemental biologics license application (sBLA) by the Food and Drug Administration (FDA) for the treatment of patients with stage 3, unresectable non-small cell lung cancer (NSCLC). The sBLA is in light of positive progression-free survival (PFS) results from the phase 3 PACIFIC trial.

Examining Immunotherapy's Role in Colorectal Cancer

November 27, 2017

“The very exciting field of checkpoint inhibitors is still evolving, and we are trying to understand where they fit in the world of CRC therapy,” said McCollum, a hematologist and medical oncologist at Texas Oncology.

Combination Continues to Show Impressive Outcomes in Melanoma

November 03, 2017

In an interview with CURE, Postow, a medical oncologist specializing in melanoma at Memorial Sloan Kettering Cancer Center, discussed the impressive efficacy seen with combining BRAF and MEK inhibitors for patients with melanoma.

Promising Myelofibrosis Therapies Are in the Pipeline

October 29, 2017

While the use of Jakafi (ruxolitinib) is firmly rooted in the treatment paradigm for patients with myelofibrosis, other novel agents, such as momelotinib and pacritinib are also gaining the interest of researchers in the field.

Immunotherapy Combination Sparks a Response in Melanoma Brain Metastases

October 23, 2017

The combination of the immunotherapies Opdivo (nivolumab) and Yervoy (ipilimumab) sparked a response in nearly half of asymptomatic patients with melanoma brain metastases who had not received prior local therapy to the brain.

Intralesional Combinations Are Promising in Melanoma

October 19, 2017

Intralesional therapies – those delivered directly to the tumor site – used in conjunction with checkpoint inhibitors have shown improvements to the treatment of people with melanoma, says Robert Andtbacka, M.D., in a presentation at the 2017 World Congress of Melanoma.

Combinations May Be Crucial for Immunotherapy in Ovarian Cancer

September 26, 2017

The future for immunotherapy treatment for gynecologic cancers may be found in drug combinations, according to Dmitriy Zamarin, M.D., Ph.D., who admits that these agents have been slower to demonstrate progress in this group of patients.

BRCA Mutations May Cause Drug Resistance in Breast and Ovarian Cancer

September 04, 2017

There is a relationship between the genetics of BRCA1 and BRCA2 mutations and the risk of a patient with breast or ovarian cancer being resistant to platinum-based chemotherapy, according to recent research conducted at the Perelman School of Medicine at the University of Pennsylvania. The study’s senior author Katherine Nathanson, M.D., spoke with CURE about these findings.

Identifying Rare Biomarker Could Help a Subset of Patients With Lung Cancer

August 31, 2017

RET rearrangements, while they only occur in about 1 percent of patients with non-small cell lung cancer, are nevertheless an important biomarker to identify, since targeted agents have proven to be beneficial in this patient population, and realizing a patient has the mutation can greatly impact their treatment plan, says Christine M. Lovly, M.D., Ph.D.

Understanding Genomic Testing in Breast Cancer

August 24, 2017

Medicine is becoming more personalized for patients with breast cancer as physicians continue to understand both the disease itself and genomic testing that can lead to more optimal treatment plans.

A Promising New Agent for Epithelial Ovarian Cancer

August 15, 2017

A new agent showed a favorable toxicity profile for patients with epithelial ovarian cancer. The drug, mirvetuximab soravtansine (IMGN853), also demonstrated encouraging clinical activity in a phase 1 trial presented at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting.